A Phase II Translational Study of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia Patients.
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 02 Oct 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014, as per ClinicalTrials.gov record.
- 02 Oct 2014 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.
- 21 Jan 2012 New trial record